Home Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab
 

Keywords :   


Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

2016-07-21 22:30:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the U.S. Food and Drug Administration (FDA) has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application (BLA) for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: application update agent regulatory

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
29.03Boston University Researchers Create Novel Scale To Measure Hyperpigmentation
29.03Post Office scandal: Calls for police to investigate after BBC report
29.03Researchers Look at Cinnamic Acid for Hair Growth
29.03Chinese smartphone giant takes on Tesla
29.03Questions raised over Temu cash 'giveaway' offer
29.03Charge of 90 to clear problem debt axed for poorest
29.03India's army of gold refiners face new competition
28.03Secret papers show Post Office knew case was false
More »